Introduction
============

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is applied successfully to the treatment of many hematopoietic malignancies, but remains limited by severe acute graft-versus-host-disease (aGvHD). Despite prophylactic treatment of the patients with immunosuppressive drugs after allo-HSCT, GvHD is still associated with non-relapse mortality (NRM) and contributes around 25% of NRM. ([@B19]) T-cell depletion of the graft by CD34-enrichment has been found to be the most effective method to prevent GvHD, but this leads to an increased risk of leukemic relapse in about 80% of patients ([@B14]; [@B11]). Leukemic relapse can be treated by donor leukocyte infusion (DLI; [@B12]; [@B16]; [@B17]), providing evidence for an immunological graft-versus-leukemia effect (GvL). Thus, prophylactic transfusion of donor T-cells has been included in many protocols, despite the increased risk for acute GvHD ([@B15]). Acute GvHD contributes significantly to non-relapse morbidity and mortality (NRM), thus prevention or control of this severe complication is necessary.

T-cells are optimal targets for retroviral gene transfer and stability of transduced T-cells has been shown even for several years ([@B13]; [@B18]; [@B22]; [@B8]; [@B26]; [@B7]; [@B4]). The expression of suicide genes has been shown to be effective to control GvHD, while retaining the positive effects of T-cells like GvL-activity ([@B3]; [@B1]; [@B7]; [@B4]). Clinical trials with HSV-TK transduced donor T-cells were initiated early in France, Italy and Germany and have been previously published ([@B3]; [@B7]; [@B4]). Transduced donor T-cells were transfused either immediately after hematopoietic stem cell transplantation (HSCT) on day 0 ([@B8]; [@B9]), on day +40 ([@B7]) or after day +60 ([@B4]). Eight patients from the first NGFR-HSV-TK-studies developed acute (*n* = 6) or chronic GvHD (*n* = 2), which resolved after treatment with GCV alone in seven of eight patients. Immunization against HSV-TK epitopes was observed in one patient at MHH and led to premature elimination of transduced T cells ([@B4]). The chance to get immunized strictly depended on the presence of an active immune system at the time of transfusion of transduced T-cells ([@B23]). At Hannover proteomic monitoring was added to predict pending, severe aGvHD to patients included after 2005 \[10 of 12 acute myeloid leukemia (AML) patients; [@B28], [@B27]\]. Here, we analyzed the long term outcome of all patients treated at MHH with genetically modified T-cells and compare the outcome of mismatched transplantation in combination with prophylactic DLI to unmodified DLI-treatment of relapse.

Materials and Methods {#s1}
=====================

Study Protocol
--------------

### Case Description

Seventeen patients, 15 with AML and two with chronic myelogenous leukemia (CML), were transplanted from their HLA-identical (*n* = 9) or haploidentical (*n* = 8) family donors with CD34-enriched stem cells without further immunosuppression (**Table [1](#T1A){ref-type="table"}**). Eleven received transduced donor lymphocytes according to either one of the protocols (**Figure [1](#F1){ref-type="fig"}**). The clinical protocols were approved by the ethic committee of the Hannover Medical School (protocol numbers 2157 or 3644) and by the national committee for somatic gene therapy of the "Bundesärztekammer" (No 53 or No 76) and the Paul-Ehrlich-Institute (1274). In addition, both trials were registered at the German register of gene therapy trials.

###### 

Patient clinical characteristics: all patients were transplanted with CD34-enriched donor cells from their HLA-identical siblings or haploidentical family donors.

  Table [1](#T1A){ref-type="table"}: clinical data   All patients (*n* = 17)   Table [1](#T1A){ref-type="table"}   All patients (*n* =
  -------------------------------------------------- ------------------------- ----------------------------------- ---------------------
  **Age**                                            35 (18--63)               **GvHD-Pro**                        
  **Disease**                                                                  CSA/MTX                             0
  Acute (AML, ALL, sAML)                             15                        CSA/MMF                             1
  Chronic (MDS, MPS, CML, CLL)                       2                         TCD                                 11
  **Status**                                                                   **ATG, Thymo**                      14
  CR 1/CP1                                           14                        None                                3
  CR 2 or higher                                     2                         **Donor**                           
  No CR (untreated, relapse, refr.)                  1                         Related                             17
  **Conditioning**                                                             Unrelated                           0
  Myeloablative (TBI/Cy)                             9                         **HLA-match**                       
  RIC                                                8                         Matched                             9
  **Graft**                                                                    Mismatched                          8
  PBSC                                               17                        **Gender**                          
  Bone marrow                                        1^∗^                      Female/male                         9/8
  **HSV-TK DLI**                                     11                        m/f donor                           4
  None                                               6                         **Alive**                           **11**

Donors' gender and age are shown under "donor." Transduced T-cells were transfused after day +60 or day +42 (MMRD).

∗

PBSC (CD6-depleted) +BM.

###### 

Patient follow up after sibling (MRD) HSCT and HSVTk transfer: acute and chronic GvHD after HSCT or DLI were monitored and are shown in table.

  UPN        aGvHD   cGvHD   DLI   aGvHD_DLI (days)   aGvHD\_ DLI grade   cGvHD\_ DLI   cGvHD\_ DLI grade (days)   Days\_ HSCT   Relapse   relapse_day   Years HSCT_FU   Survival   comments/cause of death
  ---------- ------- ------- ----- ------------------ ------------------- ------------- -------------------------- ------------- --------- ------------- --------------- ---------- --------------------------
  914        No      No      Yes   Yes                4 (93)              Yes           Mild (451)                 451           No                      12,4            Yes        
  919        No      No      Yes   No                                     No                                                     No                      12,2            Yes        
  1021       No      No      Yes   No                                     Yes           Severe (2626)              2626          Yes       2452          10,6            Yes        ECP for chronic
  1040       No      No      Yes   No                                     No                                                     Yes       960           **5,2**         No         relapse
  1048       No      No      Yes   No                                     No                                                     No                      7,6             Yes        
  1108       No      No      Yes   No                                     No                                                     No                      9,9             Yes        
  1159       No      No      Yes   Yes                1 (192)             No                                                     No                      8,1             Yes        
  1190       No      No      Yes   No                                     No                                                     No                      8,6             Yes        
  1208       No      No      Yes   No                                     No                                                     Yes       435           **2,0**         No         
  **1208**   Yes     No      No    n.a.               3 (97)                                                                     No                      5,7             No         MOF sepsis post-2nd HSCT
  **1040**   No      No      Yes   No                                     No                                                     Yes       520           2,5             No         Relapse post-2nd HSCT

In addition relapse, survival and cause of death are summarized. Two patients relapsed and have been transplanted for a second time. Outcome of second HSCT shown in table. n.a., not applicable;

FU

(follow up until death after 2nd HSCT);

1040 and 1208,

2nd HSCT due to relapse.

###### 

Clinical characteristics, and follow-up after haplo-HSCT (MMRD) with and without HSV-TK gene transfer: patient and donor characteristics acute and chronic GvHD are summarized for two patients with HSV-TK T-cells and six control patients without gene transduced DLI.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  UPN    Age   Gender   DIAGN_PR   FAB-\            Status              HLA-donor   Source    Conditioning                 GvHD_Proph   Acute GvHD       aGvHD-days   aGvHD_grade   ChrGvHD   CGvHD grade (days)
                                   classification                                                                                                                                             
  ------ ----- -------- ---------- ---------------- ------------------- ----------- --------- ---------------------------- ------------ ---------------- ------------ ------------- --------- --------------------
  1505   23    f        AML        M4/M5            CR 1                MMRD        PBPC      Flu/Mel ph/Thiotepa/ATG      TCD          Yes (post-DLI)   131          II            No        

  1550   25    m        AML        MO               Induction failure   MMRD        KM+PBPC   Flamsa(TBI)/ATG              CSA/MTX      No               n.a.                       Unknown   

  1551   32    f        AML        M5b              CR 2                MMRD        PBPC      Flu/Mel ph/Thiotepa/ATG      TCD          No               n.a.                       n.a.      

  1438   34    m        AML        M5b              CR 1                MMRD        PBPC      Flu/Mel ph/Thiotepa/ATG      TCD          No               n.a.                       No        

  1269   18    m        AML        M5a              CR 1                MMRD        PBPC      Flu/Mel ph/Thiotepa/ATG      TCD          ja               54           I             Yes       

  1272   38    m        AML        n.d.             CR 1                MMRD        PBPC      Bu/Cy/ATG                    CSA/MTX      No               n.a.                       Yes       Limited (131)

  1455   63    m        AML        M2               CR 2                MMRD        PBPC      Flu/Mel ph/Thiotepa/ATG      TCD          No               n.a.                       Yes       Limited (117)

  1524   58    f        AML        M**O**           CR 1                MMRD        PBPC      Flamsa (w/o AMSA)(TBI)/ATG   CSA/MMF      ja               30           I             No        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

CMV-reactivation and immune reconstitution after MMRD-HSCT: summarizes the data after transplantation for 1505 and 1550 with respect to immune reconstitution of CMV-specific CTL.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  UPN    Age   Diagnosis   Tx (Tet-table)   HLA recipient   Donor   HLA-donor CMv+   Days post-HSCT   CD3+/μl   CD8+/μl   CD4+/μl   CD8+ count OK? (\> =50)   A0201 % CD3+CD8+   A0201/μl   A2402 % der CD3+CD8+   Absolute number\   All CMV+ T-Zellen/μ l   EBV A0201 % der\   EBV A0201/μl   Comment(s)
                                                                                                                                                                                                                   A2402/μ l                                  CD3+CD8+                          
  ------ ----- ----------- ---------------- --------------- ------- ---------------- ---------------- --------- --------- --------- ------------------------- ------------------ ---------- ---------------------- ------------------ ----------------------- ------------------ -------------- ------------------
  1505   23    AML         2.2.2007         A02/A24         MMRD    A02 A24          -50              1301      517       673       Yes                       0.22               1          0.05                   0                  **1**                   0.07               0              Prior HSCT

  1505   23    AML         2.2.2007         A02/A24         MMRD    A02 A24          28               3         2         1         No                        0.00               0          0.00                   0                  **0**                   0.87               0              

  1505   23    AML         2.2.2007         A02/A24         MMRD    A02 A24          55               27        5         13        No                        0.00               0          0.00                   0                  **0**                   0.42               0              

  1505   23    AML         2.2.2007         A02/A24         MMRD    A02 A24          77               3263      2960      251       Yes                       0.01               0          0.06                   2                  **2**                   0.01               0              

  1505   23    AML         2.2.2007         A02/A24         MMRD    A02 A24          83               3944      3549      315       Yes                       0.01               0          0.12                   4                  **5**                   0.22               8              

  1505   23    AML         2.2.2007         A02/A24         MMRD    A02 A24          90               2071      1603      386       Yes                       0.03               2          2.04                   33                 **35**                  1.81               29             Clear population

  1505   23    AML         2.2.2007         A02/A24         MMRD    A02 A24          97               1629      1065      452       Yes                       0.02               0          2.75                   29                 **30**                  1.74               19             GVHD II skin

  1505   23    AML         2.2.2007         A02/A24         MMRD    A02 A24          137              1199      685       447       Yes                       0.01               0          0.02                   0                  **0**                   0.07               0              GVHD II skin

  1505   23    AML         2.2.2007         A02/A24         MMRD    A02 A24          143              1048      422       538       Yes                       0.02               0          3.01                   13                 **13**                  1.92               8              

  1505   23    AML         2.2.2007         A02/A24         MMRD    A02 A24          213              612       391       160       Yes                       0.00               0          0.05                   0                  **0**                   0.00               0              

  1505   23    AML         2.2.2007         A02/A24         MMRD    A02 A24          230              715       473       205       Yes                       0.00               0          0.07                   0                  **0**                   0.00               0              

  1550   25    AML         31.5.2007        A02             MMRD    A02              -29              542       232       238       Yes                       1.70               4          n.a.                   n.a.               **4**                   0.12               0              Prior HSCT

  1550   25    AML         31.5.2007        A02             MMRD    A02              32               23        16        2         No                        1.06               0          n.a.                   n.a.               **0**                   0.00               0              

  1550   25    AML         31.5.2007        A02             MMRD    A02              43               630       434       62        Yes                       0.13               1          n.a.                   n.a.               **1**                   0.00               0              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Prior HSCT (day -29) CMV-CTL could be detected, after HSCT the patient reactivated CMV und by day +32 CMV-CTL reconstitution occurred. Shown are absolute numbers of CMV-CTL after tetramer staining with HLA-

∗

A02 (pp65-NLV) tetramer. Patient 1550 (PBSC-CD6-depleted+ BM) reactivated CMV on day +32 and controlled the CMV-reactivation after treatment with GCV (no transduced DLI) and upon expansion of CMV-CTL from the graft.

![**Clinical trial flow chart.** Prior to G-Lymphapheresis were obtained prior to G-CSF-stimulation of the donor and shipped to MolMed for transduction by courier. After G-CSF-stimulation peripheral blood stem cells (PBSCs) were collected and CD34^+^ cells were selected and transplanted on day 0. The recipient of matched related donor PBSC received conditioning treatment with total body irradiation (TBI; 12 Gy) and cyclophosphamide (120 mg) and ATG (30 mg/kg). The recipients of the mismatched related donor PBSC received conditioning with Fludarabine, Melphalan, Thiotepa, and anti-thymoglobulin (ATG; 60 mg/kg). Lymphapheresis cells were transduced with SCFMM3 , and shipped to Hannover prior transfusion. HSV-TK DLI (1 × 10^7^ cells/kg BW) were administered either after day +60 (MRD) or on day +42 (MMRD; 1 × 10^6^/kg BW).](fphar-06-00076-g001){#F1}

Conditioning and Hematopoietic Stem Cell Transplantation
--------------------------------------------------------

T-cells were harvested from all donors after informed consent and shipped to Milano for transduction. Eleven patients received total body irradiation (TBI; 12 Gy) and cyclophosphamide (120 mg/kg) followed by a CD34-enriched stem cell graft from matched related donors (MRDs; **Table [1](#T1A){ref-type="table"}**). Donors received G-CSF (2 × 5 μg/kg daily) for 4--5 days and blood leukocytes were collected at the Institute for Transfusion Medicine (MHH; [@B4]). CD34-selection was performed under GMP conditions using the CliniMACS-system (Miltenyi; Bergisch Gladbach, Germany) at the Center for Cellular Therapy (former Cytonet, Hannover, Germany). At least 3.9 × 10^6^/kg CD34-positive cells were transplanted on day 0, and CD3^+^ T-cells were usually below 1 × 10^4^ cells/kg body weight (**Table [1](#T1A){ref-type="table"}**). CD34-selection was the only GvHD prophylaxis. Missing informed consent, acute GvHD grade II or more, life threatening infections, or relapse at the time of transfusion were exclusion criteria for gene therapy. Relapse and declining donor chimerism were treated with additional, non-transduced DLI (see **Table [2](#T2){ref-type="table"}**). One patient (UPN 1505) received a second transduced DLI to treat relapse.

###### 

Summary of transduced and non-transduced DLI: peripheral blood of all patients was screened routinely for the presence of transduced cells with FACS and PCR.

  UPN     Gebdat       Age_HSCT (1st and 2nd)   DLI                   DLI-days-post-HSCT   Cells/kg BW
  ------- ------------ ------------------------ --------------------- -------------------- ------------------
  914     06.07.1957   45                       DLI(HSV-TK)           71                   1 × 10E7
  914     06.07.1957   45                       DLI chimerism         178                  1 × 10E7
  91*A*   06.07.1957   45                       DLI chimerism         249                  1 × 10E7
  91*A*   06.07.1957   45                       DLI chimerism         329                  3 × 10E7
  91*A*   06.07.1957   45                       DLI chimerism         406                  5,3 × 10E7
  919     03.02.1967   35                       DLI(HSV-TK)           87                   4 × 10E6
  1021    02.12.1963   39                       DLI(HSV-TK)           113                  1,3 x10E7
  1021    02.12.1963   39                       DLIrelapse            2535                 1,8 × 10E7
  1021    02.12.1963   39                       DLIrelapse            2564                 1,12 × 10E8
  1021    02.12.1963   39                       DLIrelapse            2592                 2 × 10E8
  1040    28.12.1952   50                       Stemcell boost        191                  6 × 10E6 CD34^+^
  1040    28.12.1952   50                       DLI(HSV-TK)           330                  1 × 10E7
  1040    28.12.1952   53                       DLIprophylaxis        268                  1,03 × 10E6
  1040    28.12.1952   53                       DLIprophylaxis        304                  5 × 10E6
  1040    28.12.1952   53                       DLIprophylaxis        339                  1 × 10E7
  1040    28.12.1952   53                       DLIrelapse            535                  5 × 10E7
  1040    28.12.1952   53                       DLIrelapse            563                  1 × 10E8
  1040    28.12.1952   53                       DLIrelapse            612                  1,23 × 10E8
  1048    23.01.1965   38                       DLI(HSV-TK)           100                  1,5 × 10E7
  1108    18.02.1953   51                       DLI(HSV-TK)           126                  4 × 10E6
  1159    23.12.1968   35                       DLI(HSV-TK)           136                  7,5 x10E6
  1190    10.03.1966   38                       DLI(HSV-TK)           129                  1 × 10E7
  1208    06.12.1953   51                       DLI(HSV-TK)           73                   1,3 × 10E7
  1208    06.12.1953   51                       DLIrelapse            519                  1,8 × 10E7
  1269    10.04.1987   18                       DLIrelapse            377                  5,38 × 10E4
  1269    10.04.1987   18                       DLIrelapse            405                  1,3 × 10E5
  1269    10.04.1987   18                       DLIrelapse            433                  4,7 × 10E5
  1269    10.04.1987   18                       DLIrelapse            461                  1,27 × 10E6
  1269    10.04.1987   18                       DLIrelapse            488                  5 × 10E6
  1269    10.04.1987   18                       DLIrelapse            517                  1 × 10E7
  1269    10.04.1987   18                       DLIrelapse            545                  5,03 × 10E7
  1438    13.10.1972   34                       No                    na                   
  1550    25.04.1982   25                       No                                         
  1505    16.12.1983   23                       DLI(HSV-TK)           48                   1 × 10E6
  1505    16.12.1983   23                       DLI(HSV-TK) therapy   222                  1 × 10E6
  1551    18.08.1975   32                       DLI(HSV-TK)           42                   1 × 10E6

The number of transduced (first DLI) and non-transdcued DLI (for loss of chimerism or relapse) are shown as number of transduced cells (CD3

\+

cells) or as number of leukocytes transfused per kg body weight.

Description of the Retroviral Vector and the Transduction Protocol
------------------------------------------------------------------

Lymphapheresis material was obtained from 11/17 donors and shipped to MolMed (Italy) by courier for transduction. The replication-deficient, retroviral vector SFCMM-3 encodes the HSV-TK gene that confers sensitivity to GCV, and the truncated low affinity nerve-growth-factor-receptor gene (ΔLNGFR) serving as a positive selection marker and transduction protocols have been described previously ([@B18]; [@B2]; [@B6], [@B7]; [@B4]) Briefly, cells were expanded with OKT-3 (30 ng/ml) in RPMI1640 with 5% autologous plasma and 100 U/ml IL-2 (Chiron, USA) for 72 h. Cells were transduced by spin-inoculation with SFCMM-3-supernatant twice within 24 h in the presence of 4 μg/ml protamine sulfate and expanded for 48 h. Transduction efficiencies were determined by FACS and subsequently the cells were selected using a monoclonal antibody (anti-LNGFR-antibody, Roche, Mannheim, Germany) and immunomagnetic beads (Dynabeads; [@B25]). Transduced and selected cells were cryopreserved, while safety tests (as approved by the authorities) were accomplished and shipped to Hannover for transfusion (**Table [1](#T1A){ref-type="table"}**).

Monitoring for the Presence of Transduced T Lymphocytes
-------------------------------------------------------

Characterization and *ex vivo* detection of circulating transduced cells was planned at weekly for the first month 1, 2, 3, 4, 8, 12, 16, 20, 24, at 9 months, 12 months, and yearly thereafter. The follow up for three patients is now more than 12 years (**Tables [2](#T2){ref-type="table"}** and **[3](#T3){ref-type="table"}**). Flow cytometry (FACS; Coulter, Germany) was performed to examine the frequency and phenotype of the transferred gene-modified T-cells *in vivo* using mAbs specific to LNGFR (Roche, Mannheim, Germany), CD3, CD4, and CD8 (Coulter), respectively. Immune reconstitution was analyzed for B-, T-, natural killer cells, macrophages, and monocytes.

###### 

Long term follow up of PCR for TK-gene: summarizes the results obtained with PCR on HSV-TK gene expression.

  UPN    Days post-HSCT   Days post-DLI   Years follow-up   Material for cDNA   HSV-TK PCR result   Comments
  ------ ---------------- --------------- ----------------- ------------------- ------------------- -----------------------------------
  914    1155             1084            3,0               PBMNCs              Positive            
  914    4161             4090            11,2              CD3+                Negative            
  914    4526             4455            12,4              CD3+                Negative            Alive
  919    3664             3577            9,8               CD3+                Negative            
  919    4165             4078            11,2              CD3+                Negative            
  919    4530             4443            12,2              CD3+                Negative            Alive
  1021   857              744             2,0               PBMNCs              Positive            
  1021   2831             2718            7,4               CD3+                Negative            
  1021   3868             3755            10,60             CD3+                Negative            Alive
  1040   687              357             1,0               CD3+                Positive            
  1040   974              644             1,8               PBMNCs              Positive            
  1040   1057             727             2,90              CD3+                Negative            Relapse; re-transplantation; died
  1048   791              691             1,9               PBMNCs              Positive            
  1048   1002             902             2,5               PBMNCs              Negative            
  1048   2787             2687            7,64              CD3+                Negative            Alive
  1108   723              597             1,6               PBMNCs              Positive            
  1108   807              681             1,9               PBMNCs              Positive            
  1108   3598             3472            9,5               CD3+                Negative            Alive
  1159   365              229             0,6               PBMNCs              Negative            
  1159   640              504             1,4               CD3+                Negative            
  1159   3382             3246            8,9               CD3+                Negative            Alive
  1190   2398             2269            6,2               CD3+                Negative            
  1190   2767             2638            7,2               CD3+                Positive            
  1190   3144             3015            8,3               CD3+                Negative            Late relapse, alive
  1208   476              403             1,1               PBMNCs              Positive            
  1208   484              411             1,1               PBMNCs              Positive            
  1208   512              439             1,2               PBMNCs              Positive            Relapse; re-transplantation; died
  1505   221              173             0,5               CD3+                Positive            
  1505   250              202             0,6               CD3+                Positive            
  1505   277              229             0,6               CD3+                Negative            Died relapse
  1551   114              72              0,2               CD3+                Positive            
  1551   148              106             0,3               CD3+                Negative            
  1551   220              178             0,5               CD3+                Positive            **Died**

UPN\# (unique patient identification number), followed by sample date and days after allogeneic HSCT, days after DLI, Tx date (date of transplantation), Days post 1st or 2nd DLI (where appropriate), material from which RNA or DNA were obtained (PBMC: peripheral blood mononuclear cells; CD3: CD3-positive T-cells) and results of HSV-TK-PCR. DNA-isolation and HSV-TK-PCR were done as described in Section "Materials and Methods."

The presence of gene modified T-cells was confirmed by polymerase chain reactions (PCRs) with primers for the HSV-TK and the LNGFR-gene, as described ([@B4]).

HSV-TK-Gene, Donor-Chimerism, and T-Cell Receptor (TCR)-Vβ Family Expression
----------------------------------------------------------------------------

Transduced cells were analyzed at above mentioned time points and yearly thereafter for the presence of HSV-TK gene expression. To increase the likelihood to detect gene modified cells, PBMNC were enriched for CD3^+^/CD4^+^ and CD8^+^ T-cells. Genomic DNA was isolated using the QIAamp DNA MinElute Kit (Qiagen, Hilden) and amplified. A nested PCR had been developed for the detection of HSV-TK gene ([@B4]). The PCR was run on 1.2% agarose gels and analyzed. A summary of the results is shown in **Table [3](#T3){ref-type="table"}**.

RT-PCR-Analyses
---------------

RNA was isolated from PBMNC or CD3-enriched, CD3^+^/CD8^+^ and CD3^+^/CD4^+^ T-cells transcribed into cDNA. TCR-repertoire analyses were done using 25 vß- family specific primers, including controls for the constant region of the TCR and human ß-actin, as described ([@B21]). RT-PCR for detection of the *bcr-abl* fusion transcript was performed as proposed by the BIOMED-1 nested PCR on Taqman concerted action ([@B24]; [@B4]). PCR was performed with the T3 thermocycler (Biometra). Donor chimerism was analyzed by PCR amplification of highly polymorphic short tandem repeat (PCR-STR) sequences in peripheral blood and/or bone marrow samples as described earlier ([@B5]).

Results
=======

12 Years of Successful Transduced T-Cell Transfer at MHH
--------------------------------------------------------

Seventeen patients were transplanted from MRD or mismatched related donors (MMRDs) and eleven received gene-modified donor T-cells on day +42 (*n* = 2) or after day +60 (*n* = 9) after HSCT. Clinical and demographic data are summarized in **Table [1](#T1A){ref-type="table"}**. Lymphaphereses were prepared from 11 donors and shipped to MolMed for transduction with SCFMM-3 and enrichment for transduced T-cells with magnetic immunobeads yielded purities of more than 90% for ΔLNGFR^+^ cells, ranging from 91 to 99.1%. The patients were scheduled to receive transduced T-cells on day +42 or day +60, respectively, after matched (MRD) or haploidentical (MMRD) HSCT, if the clinical situation of the patients allowed transfusion. The first nine patients (MRD; **Table [1B](#T1B){ref-type="table"}**), received the T-cell transfusion by day +107 after HSCT (range: 71--330), the two patients receiving cells from MMRD received the HSV-TK DLI on day +42 (**Table [1C](#T1C){ref-type="table"}**). The immune reconstitution for lymphocytes was 640 CD3^+^ T-cells/μl (range: 150--1000 cells/μl) after MRD HSCT and zero for the MMRD transplant recipients.

Transfusion of Genetically Modified Donor Lymphocytes or Untransduced
---------------------------------------------------------------------

Seven patients had residual host cells prior to DLI. In six patients donor chimerism progressively increased after DLI and full donor chimerism was obtained in three patients, thus suggesting that the infusion of genetically modified donor lymphocytes may have facilitate HSCT engraftment. In T-depleted transplantation the achievement of full chimerism is particularly difficult. In accordance with this hypothesis, expansion of transduced donor lymphocytes often preceded the improvement of donor chimerism.

ΔLNGFR-positive cells were detected by FACS (up to 6.6% of CD3^+^ cells) for at least 6 months after transfusion. In two MMRD-recipients all CD3^+^ T-cells detected were transduced and of donor-origin, as expected. Patient UPN1505 reactivated CMV early after MMRD-HSCT. Transduced cells were transfused on day +42 from the CMV-seropositive donor and by day +77 CMV-CTL (*n* = 2) from the MMRD were detected (**Table [1D](#T1D){ref-type="table"}**). This was followed by an expansion of the CMV-CTL and led to the control of CMV-reactivation (**Table [1D](#T1D){ref-type="table"}**). UPN 1505 also developed aGvHD grade II (day +131; **Tables [1C](#T1C){ref-type="table"},[D](#T1D){ref-type="table"}**). GCV was given at 5 mg/kg body weight and as a result aGvHD was cleared. Unfortunately the patient developed relapse and died despite a second transfusion of HSV-TK transduced DLI on day +222 (**Tables [1C](#T1C){ref-type="table"}** and **[2](#T2){ref-type="table"}**). Patient 1550 did not receive any DLI, but CMV-CTL could be detected by day +44, providing protection against CMV-reactivation. HSV-TK gene expression was analyzed until last follow-up in all patients and a summary of the data is shown **Table [3](#T3){ref-type="table"}**. The longest follow-up for HSV-TK transduced cells was 7 years after HSCT (UPN1190), followed by 3 years (UPN914), whereas HSV-TK transduced cells were detectable for almost 2 years in another 6. One patient UPN919 lost HSV-TK gene expression after 22 months, in the absence of GCV treatment due to an immunization against transgene products ([@B4]). Thus, seven patients had detectable levels of HSV-TK for more than 1 year after HSCT, two died prior to the first year after HSCT (**Table [3](#T3){ref-type="table"}**). PCR for HSV-TK gene expression and donor chimerism are done yearly for all patients alive. To date, six patients have a follow up of more than 6 years patients, two patients had been treated 12 years ago and are both alive and well. None of the surviving patients show HSV-TK expression at last follow up (**Table [3](#T3){ref-type="table"}**).

Discussion
==========

Our data show the long term safety and efficacy of retroviral gene transfer in mature T-cells. The transfusion of transduced cells was tolerated well in all patients with no reported toxicities. Replication competent particles have not been detected and in general gene expression is lost after about 2 years. [@B7] have recently shown that transfusion of transduced CD3^+^ cells after haploidentical transplantation allows for optimal expansion of transduced cells ([@B10]). Long term transgene expression for more than 1 year was observed in seven of nine patients, five had HSV-TK expressing cells for more than 1 year. Two patients transplanted from mismatched donors died prior to day +365. Efficacy of the cells had been demonstrated by control of *bcr-abl* positivity, donor-chimerism conversion and in the MMRD-transplanted patient 1505 a cytomegalovirus-reactivation was controlled by the expansion of HSV-TK-transduced donor T-cells.

TK007 protocol called for haploidentical (MMRD) HSCT and eight patients were transplanted from haploidentical donors (MMRD) at Hannover. Only two patients received transduced DLI, the others were observed as control group for MMRD-HSCT and HSV-TK transfer. All patients receiving transduced T-cells expressed the transgenes for at least 1 year or until last follow up, if patients died prior to day +365 (**Table [3](#T3){ref-type="table"}**). In one patient an immunization against the transgenes had occurred thus the cells were lost earlier ([@B4]).

We have not detected non-functional HSV-TK genes in pour small patient cohort to date ([@B20]). ΔLNGFR expression as a selection marker allows rapid selection of the transduced cells, which may be favorable for the phenotype of the transduced cells, leaving the T-cell receptor repertoire of the transduced cells relatively intact ([@B4]) as compared to more time consuming selection methods with antibiotic resistance genes.

In our studies, two of the 11 patients treated with HSV-TK transduced T-cells so far developed aGvHD grades I or II, respectively. The patient (UPN1505) had developed acute GvHD grade II and was treated successfully with GCV, thus giving a confirmation of the feasibility of the HSV-TK gene transfer for control of acute GvHD by GCV treatment. The persistence of the transduced cells over about 2 years in the majority of the patients suggests that the transduced cells were able to engraft and expand. The expansion of the transduced cells could be linked to clinical data, such as viral infections or was seen as response to declining donor chimerism, suggesting function of transduced cells. After transfusion of the transduced cells one patient reactivated CMV early after HSCT (day +20) and upon transfusion of the transduced cells the CMV-reactivation was cleared. In one patient (UPN919) HSV-TK transduced were lost after 22 months. A low rate of immune mediated elimination of transduced cells was observed in our studies, suggesting that early add-back of TK-expressing cells is permitted, despite intrinsic immunogenicity of the viral-derived suicide gene.

In summary, the data presented here indicate that the use of SFCMM-3 transduced T-cells can be monitored in a clinical setting and is currently safe, efficient, and adequate for the proposed treatment of GvHD.
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